ModernMedicine Featured CME: Urology
Having trouble viewing this e-mail? Click here
You are subscribed as %%EMAIL_ADDRESS%%
To unsubscribe, click here
 
ModernMedicine
Featured CME: Urology
 
CME is free for registered members. Not a member?
Click here or on any link below to join the ModernMedicine Network today.
 

A History of Advances in Preventing Organ Rejection
Advances in immunosuppressive medicine have affected the alloimmune response mechanism that triggers organ rejection in renal transplantation. Appreciating these advances requires an understanding of the targets of some of the older and current immunosuppressive agents, as well as those currently in development.

Upon completion of this interactive, self-guided tutorial, participants should be able to discuss the clinical evidence that drove the shift from calcineurin inhibitors and steroids to regimens that include biologic agents; understand the roles of inflammation and inflammatory mediators in graft rejection (acute and chronic), and discuss the role of biologic inhibitors in mediating this process; and identify approved and developmental agents for graft rejection and discuss their targets, relative efficacies, and safety profiles in monotherapy or combination therapy for the management of rejection. » Go to this activity
 
Reviewing the Past, Present, and Future of Immunosuppression Therapy in Renal Transplantation
Medical professionals can enhance their knowledge of immunosuppressant therapy by understanding its past. This webcast depicts the complexities of organ rejection and strategies incorporated to minimize such incidences by first introducing a historical perspective on the topic and later transitioning into faculty-led presentations on current immunosuppressive treatments and emerging therapies in renal transplantation.

Upon completion, participants should be able to describe the pros and cons associated with the use of different classes of immunosuppressive agents for renal transplants; differentiate between induction and maintenance immunosuppression; compare and contrast different biologic agents with respect to their efficacy and safety in renal transplantation; discuss essential components of immunosuppressive management protocols; evaluate and discuss emerging and developmental immunosuppressive therapies; and develop a patient-focused management plan to bridge the gap between posttransplant patients and their surgeons/nephrologists to improve long-term patient outcomes. » Go to this activity
 
 
 
Click here to see all
Urology CME programs
 
 
 

You are subscribed to ModernMedicine.com. To unsubscribe, click here

To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.